Literature DB >> 7476922

Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides.

D Hodges1, S T Crooke.   

Abstract

We report the construction, characterization, and use of luciferase reporters to test the ability of antisense oligonucleotides to inhibit RNA splicing. beta-Globin and adenovirus introns were inserted into a luciferase cDNA, and luciferase expression was analyzed in transiently transfected cells. The adenovirus reporter expressed large amounts of luciferase, but two beta-globin constructs were inactive. RNA analyses determined that the beta-globin pre-mRNAs were not spliced. Mutagenesis of the beta-globin 5' splice site, branchpoint, and 3' splice site sequences to the adenovirus intron sequences promoted maximal splicing and luciferase activity; reciprocal changes in all three elements of the adenovirus intron eliminated luciferase activity. Wild-type and 3' splice site mutated adenovirus reporters were used to determine the ability of phosphorothioate deoxy and 2' methoxy oligonucleotides to inhibit splicing. RNase H activating oligodeoxynucleotides were better inhibitors of wild-type adenovirus expression than were 2' methoxy analogues. However, 2' methoxy oligonucleotides specific for the branchpoint were more effective inhibitors of splicing of adenovirus transcript containing the beta-globin branchpoint and 3' splice site. We suggest that pre-mRNAs with weak splice sites are potential targets for oligonucleotides that inhibit splicing by occupancy rather than cleavage of the transcripts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7476922

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

Review 1.  Strategy for designing specific antisense oligonucleotide sequences.

Authors:  M Mitsuhashi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

Review 2.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

3.  A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing.

Authors:  Ahmet Dirim Arslan; Xiaolong He; Minxiu Wang; Emily Rumschlag-Booms; Lijun Rong; William T Beck
Journal:  J Biomol Screen       Date:  2012-09-12

4.  Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.

Authors:  P Sazani; S H Kang; M A Maier; C Wei; J Dillman; J Summerton; M Manoharan; R Kole
Journal:  Nucleic Acids Res       Date:  2001-10-01       Impact factor: 16.971

Review 5.  Antisense technology: A review.

Authors:  Stanley T Crooke; Xue-Hai Liang; Brenda F Baker; Rosanne M Crooke
Journal:  J Biol Chem       Date:  2021-02-16       Impact factor: 5.157

6.  Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency.

Authors:  Timothy A Vickers; Susan M Freier; Huynh-Hoa Bui; Andrew Watt; Stanley T Crooke
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

7.  Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms.

Authors:  Timothy A Vickers; Stanley T Crooke
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

8.  RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.

Authors:  Xue-Hai Liang; Hong Sun; Joshua G Nichols; Stanley T Crooke
Journal:  Mol Ther       Date:  2017-06-27       Impact factor: 11.454

Review 9.  Molecular Mechanisms of Antisense Oligonucleotides.

Authors:  Stanley T Crooke
Journal:  Nucleic Acid Ther       Date:  2017-01-12       Impact factor: 5.486

10.  The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA.

Authors:  Timothy A Vickers; Stanley T Crooke
Journal:  Nucleic Acids Res       Date:  2015-09-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.